Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2001

View Archived Issues

ISTA finalizes data collection from Vitrase phase III trials

MethylGene and ChemBridge begin small-molecule enzyme inhibitor collaboration

New major resource and teaching center for functional genomics planned at TIGR

Merck & Co. and Celera extend osteoporosis collaboration for sixth year

Restructuring of agreements between Vical and Aventis

Phytopharm reports preliminary year-end highlights

Trial initiated to treat cognitive function in type 2 diabetes with Avandia

U.S. clearance for Elidel Cream 1% for mild to moderate eczema

Amgen and Isis enter three-year antisense collaboration

Phase Ib/II trial initiated for G-207 in brain cancer

MGI Pharma expands phase II trial of irofulven in unresectable hepatocellular carcinoma

Pharmacyclics reports phase III results for Xcytrin in brain metastases

Boston Scientific exercises option to acquire Smart Therapeutics

Efflux pump inhibitor MC-04,112 potentiates antipseudomonal activity of levofloxacin

Potent antiinfluenza agent and its ethyl ester prodrug described by Abbott at ICAAC

Pump-selective efflux pump inhibitors designed in collaborative effort

ECTA-based antibiotic NB-2001 effective against resistant beta-lactamase-producing bacteria

8-Methoxyquinolone as a promising development candidate with improved Gram-positive activity

Synthesis and preclinical profile of new fluoronaphthyridone antibiotic discussed at ICAAC

European MAA submitted for aripiprazole for treatment of schizophrenia

Dr. Reddy performs SAR in a series of oxazolidinones and selects lead

Nonimmunosuppressive compounds reported to stimulate neuronal regeneration

Novo Nordisk patents new PPAR agonists useful for diabetes and obesity

Tetracyclic CXCR1/CXCR2 receptor antagonists in development at Pfizer

Anticancer compounds synthesized at Agouron target protein kinases

Abbott presents newest discoveries for inhibiting angiogenesis

Protein farnesyltransferase inhibitors emerge from R&D at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...